China National Pharmaceutical Group Co., Ltd.
GPTKB entity
Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Sinopharm
gptkb:China_National_Pharmaceutical_Group_Corporation China_National_Pharmaceutical_Group_Co.,_Ltd._(Sinopharm) |
| gptkbp:awards |
gptkb:National_Quality_Award
gptkb:China's_Top_500_Enterprises Best Employer Award |
| gptkbp:CEO |
Liang_Zhiqiang
|
| gptkbp:collaborations |
government agencies
academic institutions international health organizations |
| gptkbp:employees |
over 100,000
|
| gptkbp:founded |
1998
|
| gptkbp:globalPresence |
gptkb:Asia
Africa Americas Europe over 100 countries |
| gptkbp:headquarters |
gptkb:Beijing,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
China National Pharmaceutical Group Co., Ltd.
|
| gptkbp:investmentFocus |
biotechnology
medical research healthcare_sector |
| gptkbp:market |
gptkb:China
international over $50 billion (2021) |
| gptkbp:operatesIn |
pharmaceutical industry
|
| gptkbp:parentCompany |
gptkb:State-owned_Assets_Supervision_and_Administration_Commission
|
| gptkbp:partnerships |
UNICEF
WHO |
| gptkbp:philanthropy |
disaster relief efforts
medical assistance programs healthcare_donations |
| gptkbp:products |
medical devices
generic drugs vaccines biopharmaceuticals diagnostic_kits |
| gptkbp:researchAndDevelopment |
clinical trials
pharmaceutical research vaccine development |
| gptkbp:revenue |
over $30 billion (2020)
|
| gptkbp:stockExchange |
gptkb:Shanghai_Stock_Exchange
|
| gptkbp:stockSymbol |
601607
|
| gptkbp:subsidiary |
gptkb:Sinopharm_Group
|
| gptkbp:sustainabilityInitiatives |
environmental protection
corporate social responsibility community health programs |
| gptkbp:website |
www.sinopharm.com
|